Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss

Laryngoscope

Volumn 116, Issue 2, 2006, Pages 201-206

  Zehnder, Andreas F ^a,b,c   Kristiansen, Arthur G ^b   Adams, Joe C ^a,b   Kujawa, Sharon G ^a,b   Merchant, Saumil N ^a,b   McKenna, Michael J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c HNO Universitatsklinik   (Switzerland)

Author keywords

Bone remodeling; Osteoprotegerin (OPG); Otic capsule; RANK ligand (RANKL); Receptor activator of nuclear factor Kappa B (RANK)

Indexed keywords

OSTEOPROTEGERIN; CELL RECEPTOR; GLYCOPROTEIN; TNFRSF11B PROTEIN, HUMAN; TNFRSF11B PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE REMODELING; BRAIN STEM RESPONSE; CONTROLLED STUDY; DISTORTION PRODUCT OTOACOUSTIC EMISSION; EAR; HEARING; HEARING ACUITY; HEARING LOSS; HISTOLOGY; MICROSCOPY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOSCLEROSIS; PATHOPHYSIOLOGY; PERILYMPH; PRIORITY JOURNAL; ANIMAL; AUDITORY STIMULATION; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; EVOKED BRAIN STEM AUDITORY RESPONSE; GENETICS; INNER EAR; MOUSE MUTANT; PHYSIOLOGY; TEMPORAL BONE;

ACOUSTIC STIMULATION; ANIMALS; BONE REMODELING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EAR, INNER; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; GLYCOPROTEINS; HEARING LOSS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TEMPORAL BONE;

EID: 33645785609     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000191466.09210.9a     Document Type: Article

References (14)

1. Frisch T, Sorensen MS, Overgaard S, et al. Estimation of volume referent bone turnover in the otic capsule after sequential point labeling. Ann Otol Rhinol Laryngol 2000;109:33-39.
2. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001;92:460-470.
3. Udagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000;141:3478-3484.
4. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
5. Zehnder AF, Kristiansen AG, Adams JC, et al. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. Laryngoscope 2005;115:172-177.
6. Chole RA. Differential osteoclast activation in endochondral and intramembranous bone. Ann Otol Rhinol Laryngol 1993;102:616-619.
7. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;24:610-615.
8. Kujawa SG, Liberman MC. Long-term sound conditioning enhances cochlear sensitivity. J Neurophysiol 1999;82:863-873.
9. Lim DJ, Saunders WH. Active otosclerotic foci in the stapes. An electron microscopic study. Acta Otolaryngol 1975;80:255-268.
10. Parahy C, Linthicum FH Jr. Otosclerosis and otospongiosis: clinical and histological comparisons. Laryngoscope 1984;94:508-512.
11. Parahy C, Linthicum FH Jr. Otosclerosis: relationship of spiral ligament hyalinization to sensorineural hearing loss. Laryngoscope 1983;93:717-720.
12. Schuknecht HF, Barber W. Histologic variants in otosclerosis. Laryngoscope 1985;95:1307-1317.
13. Hequembourg S, Liberman MC. Spiral ligament pathology: a major aspect of age-related cochlear degeneration in C57BL/6 mice. J Assoc Res Otolaryngol 2001;2:118-129.
14. Adams JC. Clinical implications of inflammatory cytokines in the cochlea: a technical note. Otol Neurotol 2002;23:316-322.